Please ensure Javascript is enabled for purposes of website accessibility
CASE REPORT
Good distant outcome of treatment of a patient with advanced gastric cancer
 
More details
Hide details
 
Submission date: 2014-11-28
 
 
Acceptance date: 2015-01-26
 
 
Publication date: 2015-03-24
 
 
Medical Studies 2015;31(1):52-55
 
KEYWORDS
TOPICS
ABSTRACT
The case of a patient is presented who had undergone surgical procedure of total gastrectomy, including the greater and lesser omentum, spleen, tail of the pancreas, splenic flexure of the colon, part of the diaphragm, and D2 lymphadenectomy, due to advanced gastric cancer T4bN3M0. The study covers a 9-year period of observations and check-up examinations performed on this patient. During all that time the patient remained in a good general condition, without features of cancer recurrence. Despite unfavourable prognosis in patients with clinical advancement of gastric cancer stage 3C, long-term survivals happen, such as in the case presented by the researchers. Most probably this is related with the biology of the tumour, which has not been fully recognised, and many prognostic factors of a given cancerous disease.
REFERENCES (15)
1.

Krajowy Rejestr Nowotworów.
 
2.

Potemski P, Polkowski W. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Via Medica 2013; 125-35.
 
3.

Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol 2013; 23: 3-9.
 
4.

Piazuelo BM, Correa P. Gastric cancer: overview. Colomb Med 2013; 44: 192-201.
 
5.

Olszewska M, Głuszek S. New possibilities for the treatment of gastric cancer. Studia Medyczne 2013; 29: 343-8.
 
6.

Park D, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-9.
 
7.

Bilici A. Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol 2014; 20: 3905-15.
 
8.

Li LF, Wei ZJ, Sun H, et al. Abnormal beta-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis. World J Gastroenterol 2014; 20: 12313-21.
 
9.

Scartozzi M, Galizia E, Freddari F, et al. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 2004; 30: 451-9.
 
10.

Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects. World J Gastroenterol 2014; 20: 4526-35.
 
11.

Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer – a systematic analysis of data from the literature. J Cancer 2012; 3: 137-44.
 
12.

Ku GY, Ilson DH. Esophagogastric cancer: targeted agent. Cancer Treat Rev 2010; 36: 235-48.
 
13.

Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 2009; 21: 381-5.
 
14.

Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol 2002; 8: 591-5.
 
15.
v Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-9.
 
eISSN:2300-6722
ISSN:1899-1874
Journals System - logo
Scroll to top